Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Vivos Therapeutics Inc.

    NASDAQ: VVOS · Real-Time Price · USD
    2.22
    0.08 (3.74%)
    At close: Jun 16, 2025, 3:59 PM
    2.22
    0.00%
    After-hours: Jun 16, 2025, 07:59 PM EDT

    Vivos Therapeutics Statistics

    Share Statistics

    Vivos Therapeutics has 5.89M shares outstanding. The number of shares has increased by 73.39% in one year.

    Shares Outstanding

    n/a
    		 5.89M

    Shares Change (YoY)

    n/a
    		 73.39%

    Shares Change (QoQ)

    n/a
    		 21.8%

    Owned by Institutions (%)

    n/a
    		 7.94%

    Shares Floating

    n/a
    		 4.59M

    Failed to Deliver (FTD) Shares

    n/a
    		 937

    FTD / Avg. Volume

    n/a
    		 0.92%

    Short Selling Information

    The latest short interest is 305.5K, so 5.19% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 305.5K

    Short % of Shares Out

    n/a
    		 5.19%

    Short % of Float

    n/a
    		 5.76%

    Short Ratio (days to cover)

    n/a
    		 1.75

    Valuation Ratios

    The PE ratio is -1.93 and the forward PE ratio is -2.27. Vivos Therapeutics's PEG ratio is 0.02.

    PE Ratio

    n/a
    		 -1.93

    Forward PE

    n/a
    		 -2.27

    PS Ratio

    n/a
    		 1.43

    Forward PS

    n/a
    		 0.7

    PB Ratio

    n/a
    		 2.71

    P/FCF Ratio

    n/a
    		 -1.62

    PEG Ratio

    n/a
    		 0.02
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Vivos Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.5, with a Debt / Equity ratio of 0.19.

    Current Ratio

    n/a
    		 1.5

    Quick Ratio

    n/a
    		 1.5

    Debt / Equity

    n/a
    		 0.19

    Debt / EBITDA

    n/a
    		 -0.14

    Debt / FCF

    n/a
    		 -0.11

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $137,899.08

    Profits Per Employee

    n/a
    		 $-102,165.14

    Employee Count

    n/a
    		 109

    Asset Turnover

    n/a
    		 0.98

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 8.29% in the last 52 weeks. The beta is 6.99, so Vivos Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 6.99

    52-Week Price Change

    n/a
    		 8.29%

    50-Day Moving Average

    n/a
    		 2.45

    200-Day Moving Average

    n/a
    		 3.23

    Relative Strength Index (RSI)

    n/a
    		 44.23

    Average Volume (20 Days)

    n/a
    		 101,706

    Income Statement

    In the last 12 months, Vivos Therapeutics had revenue of 15.03M and earned -11.14M in profits. Earnings per share was -1.68.

    Revenue

    n/a
    		 15.03M

    Gross Profit

    n/a
    		 9.02M

    Operating Income

    n/a
    		 -11.17M

    Net Income

    n/a
    		 -11.14M

    EBITDA

    n/a
    		 -10.55M

    EBIT

    n/a
    		 -11.17M

    Earnings Per Share (EPS)

    n/a
    		 -1.68
    Full Income Statement

    Balance Sheet

    The company has 6.26M in cash and 1.51M in debt, giving a net cash position of 4.75M.

    Cash & Cash Equivalents

    n/a
    		 6.26M

    Total Debt

    n/a
    		 1.51M

    Net Cash

    n/a
    		 4.75M

    Retained Earnings

    n/a
    		 -104.19M

    Total Assets

    n/a
    		 11.28M

    Working Capital

    n/a
    		 -1.09M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -12.69M and capital expenditures -568K, giving a free cash flow of -13.26M.

    Operating Cash Flow

    n/a
    		 -12.69M

    Capital Expenditures

    n/a
    		 -568K

    Free Cash Flow

    n/a
    		 -13.26M

    FCF Per Share

    n/a
    		 -2.64
    Full Cash Flow Statement

    Margins

    Gross margin is 60%, with operating and profit margins of -74.32% and -74.09%.

    Gross Margin

    n/a
    		 60%

    Operating Margin

    n/a
    		 -74.32%

    Pretax Margin

    n/a
    		 -74.09%

    Profit Margin

    n/a
    		 -74.09%

    EBITDA Margin

    n/a
    		 -70.22%

    EBIT Margin

    n/a
    		 -74.32%

    FCF Margin

    n/a
    		 -88.21%

    Dividends & Yields

    VVOS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for VVOS is $6.1, which is 174.8% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $6.1

    Price Target Difference

    n/a
    		 174.8%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 2
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Oct 27, 2023. It was a backward split with a ratio of 1:25.

    Last Split Date

    n/a
    		 Oct 27, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:25

    Scores

    Altman Z-Score

    n/a
    		 -14.2

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist